Reference no: EM133760608

Question

Comment on this Cannabis and chronic management is a new study that is sweeping through healthcare. THC and CBD are two types of cannabinoids in the cannabis plant that are being studied in healthcare. THC is the compound that produces psychoactive effects, while CBD has no psychoactive effects (Arcangelo et al., 2022, p. 179). Cannabinoid has receptors broken down into CB1 and CB2 receptors. The receptors get messages from the endocannabinoids and carry out the message to the presynaptic neuron. This will release other neurotransmitters (Arcangelo et al., 2022, p. 181). CB1 aids in decreasing the neurotransmitter GABA. This reaction can cause effects such as changes in pain perception, appetite stimulation, and memory/cognition changes (Arcangelo et al., 2022, p. 181). CB2 has more to do with the peripheral nervous system. They also aid in releasing neurotransmitters from presynaptic neurons. This can cause effects such as positive pain control, positive effects on the immune system, and neurological disorders. In many states where cannabis is legal, it can be used for chronic pain, seizures, migraines, spasticity, post-traumatic stress disorder, irritable bowel syndrome, inflammatory bowel syndrome, and glaucoma (Hameed et al., 2023). With the increased use of cannabis for chronic diseases,